Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 83 entries
Sorted by: Best Match Show Resources per page
Correction: Modeling the Impact of Uganda's Safe Male Circumcision Program: Implications for Age and Regional Targeting.

PloS one

Kripke K, Vazzano A, Kirungi W, Musinguzi J, Opio A, Ssempebwa R, Nakawunde S, Kyobutungi S, Akao JN, Magala F, Mwidu G, Castor D, Njeuhmeli E.
PMID: 28046081
PLoS One. 2017 Jan 03;12(1):e0169699. doi: 10.1371/journal.pone.0169699. eCollection 2017.

[This corrects the article DOI: 10.1371/journal.pone.0158693.].

Cite
Kripke K, Vazzano A, Kirungi W, et al. Correction: Modeling the Impact of Uganda's Safe Male Circumcision Program: Implications for Age and Regional Targeting. PLoS One. 2017;12(1):e0169699doi: 10.1371/journal.pone.0169699.
Kripke, K., Vazzano, A., Kirungi, W., Musinguzi, J., Opio, A., Ssempebwa, R., Nakawunde, S., Kyobutungi, S., Akao, J. N., Magala, F., Mwidu, G., Castor, D., & Njeuhmeli, E. (2017). Correction: Modeling the Impact of Uganda's Safe Male Circumcision Program: Implications for Age and Regional Targeting. PloS one, 12(1), e0169699. https://doi.org/10.1371/journal.pone.0169699
Kripke, Katharine, et al. "Correction: Modeling the Impact of Uganda's Safe Male Circumcision Program: Implications for Age and Regional Targeting." PloS one vol. 12,1 (2017): e0169699. doi: https://doi.org/10.1371/journal.pone.0169699
Kripke K, Vazzano A, Kirungi W, Musinguzi J, Opio A, Ssempebwa R, Nakawunde S, Kyobutungi S, Akao JN, Magala F, Mwidu G, Castor D, Njeuhmeli E. Correction: Modeling the Impact of Uganda's Safe Male Circumcision Program: Implications for Age and Regional Targeting. PLoS One. 2017 Jan 03;12(1):e0169699. doi: 10.1371/journal.pone.0169699. eCollection 2017. PMID: 28046081; PMCID: PMC5207635.
Copy Download .nbib Format: NLM
Modeling for edge detection problems in blurred noisy images.

IEEE transactions on image processing : a publication of the IEEE Signal Processing Society

Bruni C, De Santis A, Iacoviello D, Koch G.
PMID: 18255489
IEEE Trans Image Process. 2001;10(10):1447-53. doi: 10.1109/83.951531.

The aim of this paper is to provide a theoretical set up and a mathematical model for the problem of image reconstruction. The original image belongs to a family of two-dimensional (2-D) possibly discontinuous functions, but is blurred by...

Cite
Bruni C, De Santis A, Iacoviello D, et al. Modeling for edge detection problems in blurred noisy images. IEEE Trans Image Process. 2001;10(10):1447-53doi: 10.1109/83.951531.
Bruni, C., De Santis, A., Iacoviello, D., & Koch, G. (2001). Modeling for edge detection problems in blurred noisy images. IEEE transactions on image processing : a publication of the IEEE Signal Processing Society, 10(10), 1447-53. https://doi.org/10.1109/83.951531
Bruni, C, et al. "Modeling for edge detection problems in blurred noisy images." IEEE transactions on image processing : a publication of the IEEE Signal Processing Society vol. 10,10 (2001): 1447-53. doi: https://doi.org/10.1109/83.951531
Bruni C, De Santis A, Iacoviello D, Koch G. Modeling for edge detection problems in blurred noisy images. IEEE Trans Image Process. 2001;10(10):1447-53. doi: 10.1109/83.951531. PMID: 18255489.
Copy Download .nbib Format: NLM
Assessment of the Isoniazid Preventive Therapy Uptake and Associated Characteristics: A Cross-Sectional Study.

Tuberculosis research and treatment

Birungi FM, Graham S, Uwimana J, van Wyk B.
PMID: 29854455
Tuberc Res Treat. 2018 May 06;2018:8690714. doi: 10.1155/2018/8690714. eCollection 2018.

OBJECTIVE: To assess the uptake of isoniazid preventive therapy (IPT) by eligible children in Kigali, Rwanda, and associated individual, households, and healthcare systems characteristics.METHODS: A cross-sectional study was conducted among child contacts of index cases having sputum smear-positive pulmonary...

Cite
Birungi FM, Graham S, Uwimana J, et al. Assessment of the Isoniazid Preventive Therapy Uptake and Associated Characteristics: A Cross-Sectional Study. Tuberc Res Treat. 2018;2018:8690714doi: 10.1155/2018/8690714.
Birungi, F. M., Graham, S., Uwimana, J., & van Wyk, B. (2018). Assessment of the Isoniazid Preventive Therapy Uptake and Associated Characteristics: A Cross-Sectional Study. Tuberculosis research and treatment, 20188690714. https://doi.org/10.1155/2018/8690714
Birungi, Francine Mwayuma, et al. "Assessment of the Isoniazid Preventive Therapy Uptake and Associated Characteristics: A Cross-Sectional Study." Tuberculosis research and treatment vol. 2018 (2018): 8690714. doi: https://doi.org/10.1155/2018/8690714
Birungi FM, Graham S, Uwimana J, van Wyk B. Assessment of the Isoniazid Preventive Therapy Uptake and Associated Characteristics: A Cross-Sectional Study. Tuberc Res Treat. 2018 May 06;2018:8690714. doi: 10.1155/2018/8690714. eCollection 2018. PMID: 29854455; PMCID: PMC5960530.
Copy Download .nbib Format: NLM
A Retrospective Cross Sectional Study of the Effectiveness of a Project in Improving Infant Health in Bwindi, South Western Uganda.

Frontiers in public health

Kamugisha SR, Dobson AE, Stewart AG, Haven N, Mutahunga B, Wilkinson E.
PMID: 30370265
Front Public Health. 2018 Oct 12;6:290. doi: 10.3389/fpubh.2018.00290. eCollection 2018.

No abstract available.

Cite
Kamugisha SR, Dobson AE, Stewart AG, et al. A Retrospective Cross Sectional Study of the Effectiveness of a Project in Improving Infant Health in Bwindi, South Western Uganda. Front Public Health. 2018;6:290doi: 10.3389/fpubh.2018.00290.
Kamugisha, S. R., Dobson, A. E., Stewart, A. G., Haven, N., Mutahunga, B., & Wilkinson, E. (2018). A Retrospective Cross Sectional Study of the Effectiveness of a Project in Improving Infant Health in Bwindi, South Western Uganda. Frontiers in public health, 6290. https://doi.org/10.3389/fpubh.2018.00290
Kamugisha, S Robert, et al. "A Retrospective Cross Sectional Study of the Effectiveness of a Project in Improving Infant Health in Bwindi, South Western Uganda." Frontiers in public health vol. 6 (2018): 290. doi: https://doi.org/10.3389/fpubh.2018.00290
Kamugisha SR, Dobson AE, Stewart AG, Haven N, Mutahunga B, Wilkinson E. A Retrospective Cross Sectional Study of the Effectiveness of a Project in Improving Infant Health in Bwindi, South Western Uganda. Front Public Health. 2018 Oct 12;6:290. doi: 10.3389/fpubh.2018.00290. eCollection 2018. PMID: 30370265; PMCID: PMC6194221.
Copy Download .nbib Format: NLM
Community-Based Health Insurance Increased Health Care Utilization and Reduced Mortality in Children Under-5, Around Bwindi Community Hospital, Uganda Between 2015 and 2017.

Frontiers in public health

Haven N, Dobson AE, Yusuf K, Kellermann S, Mutahunga B, Stewart AG, Wilkinson E.
PMID: 30356909
Front Public Health. 2018 Oct 09;6:281. doi: 10.3389/fpubh.2018.00281. eCollection 2018.

No abstract available.

Cite
Haven N, Dobson AE, Yusuf K, et al. Community-Based Health Insurance Increased Health Care Utilization and Reduced Mortality in Children Under-5, Around Bwindi Community Hospital, Uganda Between 2015 and 2017. Front Public Health. 2018;6:281doi: 10.3389/fpubh.2018.00281.
Haven, N., Dobson, A. E., Yusuf, K., Kellermann, S., Mutahunga, B., Stewart, A. G., & Wilkinson, E. (2018). Community-Based Health Insurance Increased Health Care Utilization and Reduced Mortality in Children Under-5, Around Bwindi Community Hospital, Uganda Between 2015 and 2017. Frontiers in public health, 6281. https://doi.org/10.3389/fpubh.2018.00281
Haven, Nahabwe, et al. "Community-Based Health Insurance Increased Health Care Utilization and Reduced Mortality in Children Under-5, Around Bwindi Community Hospital, Uganda Between 2015 and 2017." Frontiers in public health vol. 6 (2018): 281. doi: https://doi.org/10.3389/fpubh.2018.00281
Haven N, Dobson AE, Yusuf K, Kellermann S, Mutahunga B, Stewart AG, Wilkinson E. Community-Based Health Insurance Increased Health Care Utilization and Reduced Mortality in Children Under-5, Around Bwindi Community Hospital, Uganda Between 2015 and 2017. Front Public Health. 2018 Oct 09;6:281. doi: 10.3389/fpubh.2018.00281. eCollection 2018. PMID: 30356909; PMCID: PMC6190927.
Copy Download .nbib Format: NLM
Drug-Resistant Tuberculosis Presenting as a Testicular Mass: A Case Report.

International medical case reports journal

Nuwagira E, Yekosani M, Abraham B, Atwine R, Caleb T, Baluku JB.
PMID: 33688269
Int Med Case Rep J. 2021 Mar 02;14:145-149. doi: 10.2147/IMCRJ.S300216. eCollection 2021.

BACKGROUND: Extrapulmonary drug-resistant tuberculosis is extremely rare and is almost always associated with poor treatment outcomes. This is partly due to the difficulty in confirming the diagnosis.CASE PRESENTATION: A 40-year-old HIV-negative male presented with a painless scrotal mass, low-grade...

Cite
Nuwagira E, Yekosani M, Abraham B, et al. Drug-Resistant Tuberculosis Presenting as a Testicular Mass: A Case Report. Int Med Case Rep J. 2021;14:145-149doi: 10.2147/IMCRJ.S300216.
Nuwagira, E., Yekosani, M., Abraham, B., Atwine, R., Caleb, T., & Baluku, J. B. (2021). Drug-Resistant Tuberculosis Presenting as a Testicular Mass: A Case Report. International medical case reports journal, 14145-149. https://doi.org/10.2147/IMCRJ.S300216
Nuwagira, Edwin, et al. "Drug-Resistant Tuberculosis Presenting as a Testicular Mass: A Case Report." International medical case reports journal vol. 14 (2021): 145-149. doi: https://doi.org/10.2147/IMCRJ.S300216
Nuwagira E, Yekosani M, Abraham B, Atwine R, Caleb T, Baluku JB. Drug-Resistant Tuberculosis Presenting as a Testicular Mass: A Case Report. Int Med Case Rep J. 2021 Mar 02;14:145-149. doi: 10.2147/IMCRJ.S300216. eCollection 2021. PMID: 33688269; PMCID: PMC7936665.
Copy Download .nbib Format: NLM
Oral .

Microorganisms

Melchiorre D, Ceccherini MT, Romano E, Cometi L, El-Aoufy K, Bellando-Randone S, Roccotelli A, Bruni C, Moggi-Pignone A, Carboni D, Guiducci S, Lepri G, Tofani L, Pietramellara G, Matucci-Cerinic M.
PMID: 34203626
Microorganisms. 2021 Jun 15;9(6). doi: 10.3390/microorganisms9061298.

In systemic sclerosis (SSc), the gastrointestinal tract (GIT) plays a central role in the patient's quality of life. The microbiome populates the GIT, where a relationship between the

Cite
Melchiorre D, Ceccherini MT, Romano E, et al. Oral . Microorganisms. 2021;9(6)doi: 10.3390/microorganisms9061298.
Melchiorre, D., Ceccherini, M. T., Romano, E., Cometi, L., El-Aoufy, K., Bellando-Randone, S., Roccotelli, A., Bruni, C., Moggi-Pignone, A., Carboni, D., Guiducci, S., Lepri, G., Tofani, L., Pietramellara, G., & Matucci-Cerinic, M. (2021). Oral . Microorganisms, 9(6), . https://doi.org/10.3390/microorganisms9061298
Melchiorre, Daniela, et al. "Oral ." Microorganisms vol. 9,6 (2021). doi: https://doi.org/10.3390/microorganisms9061298
Melchiorre D, Ceccherini MT, Romano E, Cometi L, El-Aoufy K, Bellando-Randone S, Roccotelli A, Bruni C, Moggi-Pignone A, Carboni D, Guiducci S, Lepri G, Tofani L, Pietramellara G, Matucci-Cerinic M. Oral . Microorganisms. 2021 Jun 15;9(6). doi: 10.3390/microorganisms9061298. PMID: 34203626; PMCID: PMC8232208.
Copy Download .nbib Format: NLM
Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.

Autoimmunity reviews

Agostini E, De Luca G, Bruni C, Bartoli F, Tofani L, Campochiaro C, Pacini G, Moggi-Pignone A, Guiducci S, Bellando-Randone S, Shoenfeld Y, Dagna L, Matucci-Cerinic M.
PMID: 34718166
Autoimmun Rev. 2021 Dec;20(12):102981. doi: 10.1016/j.autrev.2021.102981. Epub 2021 Oct 28.

INTRODUCTION: Intravenous immunoglobulins (IVIG) are a new therapeutic approach in systemic sclerosis SSc. An immunomodulatory and antifibrotic activity has been postulated. IVIG are generally well tolerated and have only rare side effects. Our retrospective study focused its attention on...

Cite
Agostini E, De Luca G, Bruni C, et al. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. Autoimmun Rev. 2021;20(12):102981doi: 10.1016/j.autrev.2021.102981.
Agostini, E., De Luca, G., Bruni, C., Bartoli, F., Tofani, L., Campochiaro, C., Pacini, G., Moggi-Pignone, A., Guiducci, S., Bellando-Randone, S., Shoenfeld, Y., Dagna, L., & Matucci-Cerinic, M. (2021). Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. Autoimmunity reviews, 20(12), 102981. https://doi.org/10.1016/j.autrev.2021.102981
Agostini, Elana, et al. "Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience." Autoimmunity reviews vol. 20,12 (2021): 102981. doi: https://doi.org/10.1016/j.autrev.2021.102981
Agostini E, De Luca G, Bruni C, Bartoli F, Tofani L, Campochiaro C, Pacini G, Moggi-Pignone A, Guiducci S, Bellando-Randone S, Shoenfeld Y, Dagna L, Matucci-Cerinic M. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. Autoimmun Rev. 2021 Dec;20(12):102981. doi: 10.1016/j.autrev.2021.102981. Epub 2021 Oct 28. PMID: 34718166.
Copy Download .nbib Format: NLM
The burning question: To use or not to use cyclophosphamide in systemic sclerosis.

European journal of rheumatology

Bruni C, Furst DE.
PMID: 33164737
Eur J Rheumatol. 2020 Oct;7:S237-S241. doi: 10.5152/eurjrheum.2020.19104. Epub 2020 Oct 01.

Fibrosis, inflammation, and vasculopathy are the main determinants of systemic sclerosis (SSc) pathogenesis. Cyclophosphamide (CYC), an alkylating agent, has been used to treat skin fibrosis and interstitial lung diseases in SSc for many years and still represents a mainstay...

Cite
Bruni C, Furst DE. The burning question: To use or not to use cyclophosphamide in systemic sclerosis. Eur J Rheumatol. 2020;7:S237-S241doi: 10.5152/eurjrheum.2020.19104.
Bruni, C., & Furst, D. E. (2020). The burning question: To use or not to use cyclophosphamide in systemic sclerosis. European journal of rheumatology, 7S237-S241. https://doi.org/10.5152/eurjrheum.2020.19104
Bruni, Cosimo, and Furst, Daniel E. "The burning question: To use or not to use cyclophosphamide in systemic sclerosis." European journal of rheumatology vol. 7 (2020): S237-S241. doi: https://doi.org/10.5152/eurjrheum.2020.19104
Bruni C, Furst DE. The burning question: To use or not to use cyclophosphamide in systemic sclerosis. Eur J Rheumatol. 2020 Oct;7:S237-S241. doi: 10.5152/eurjrheum.2020.19104. Epub 2020 Oct 01. PMID: 33164737; PMCID: PMC7647679.
Copy Download .nbib Format: NLM
Next generation economics of universal HIV treatment.

The Lancet. Global health

Birungi C.
PMID: 34919846
Lancet Glob Health. 2022 Jan;10(1):e12-e13. doi: 10.1016/S2214-109X(21)00560-X.

No abstract available.

Cite
Birungi C. Next generation economics of universal HIV treatment. Lancet Glob Health. 2022;10(1):e12-e13doi: 10.1016/S2214-109X(21)00560-X.
Birungi, C. (2022). Next generation economics of universal HIV treatment. The Lancet. Global health, 10(1), e12-e13. https://doi.org/10.1016/S2214-109X(21)00560-X
Birungi, Charles. "Next generation economics of universal HIV treatment." The Lancet. Global health vol. 10,1 (2022): e12-e13. doi: https://doi.org/10.1016/S2214-109X(21)00560-X
Birungi C. Next generation economics of universal HIV treatment. Lancet Glob Health. 2022 Jan;10(1):e12-e13. doi: 10.1016/S2214-109X(21)00560-X. PMID: 34919846.
Copy Download .nbib Format: NLM
Next generation economics of universal HIV treatment.

The Lancet. Global health

Birungi C.
PMID: 34919846
Lancet Glob Health. 2022 Jan;10(1):e12-e13. doi: 10.1016/S2214-109X(21)00560-X.

No abstract available.

Cite
Birungi C. Next generation economics of universal HIV treatment. Lancet Glob Health. 2022;10(1):e12-e13doi: 10.1016/S2214-109X(21)00560-X.
Birungi, C. (2022). Next generation economics of universal HIV treatment. The Lancet. Global health, 10(1), e12-e13. https://doi.org/10.1016/S2214-109X(21)00560-X
Birungi, Charles. "Next generation economics of universal HIV treatment." The Lancet. Global health vol. 10,1 (2022): e12-e13. doi: https://doi.org/10.1016/S2214-109X(21)00560-X
Birungi C. Next generation economics of universal HIV treatment. Lancet Glob Health. 2022 Jan;10(1):e12-e13. doi: 10.1016/S2214-109X(21)00560-X. PMID: 34919846.
Copy Download .nbib Format: NLM
Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience.

Therapeutic advances in musculoskeletal disease

Tesei G, Cometi L, Nacci F, Terenzi R, Tofani L, Capassoni M, Bartoli F, Fiori G, Matucci-Cerinic M, Bruni C.
PMID: 34025783
Ther Adv Musculoskelet Dis. 2021 May 10;13:1759720X211014019. doi: 10.1177/1759720X211014019. eCollection 2021.

BACKGROUND: Ultrasound (US) is useful in monitoring RA patients, with the US7 score allowing grey-scale and power-Doppler (PD) semi-quantitative evaluation of synovitis and teno-synovitis. We evaluated real-life efficacy and safety of Baricitinib, an oral selective JAK1-2 inhibitor, in RA...

Cite
Tesei G, Cometi L, Nacci F, et al. Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014019doi: 10.1177/1759720X211014019.
Tesei, G., Cometi, L., Nacci, F., Terenzi, R., Tofani, L., Capassoni, M., Bartoli, F., Fiori, G., Matucci-Cerinic, M., & Bruni, C. (2021). Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience. Therapeutic advances in musculoskeletal disease, 131759720X211014019. https://doi.org/10.1177/1759720X211014019
Tesei, Giulia, et al. "Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience." Therapeutic advances in musculoskeletal disease vol. 13 (2021): 1759720X211014019. doi: https://doi.org/10.1177/1759720X211014019
Tesei G, Cometi L, Nacci F, Terenzi R, Tofani L, Capassoni M, Bartoli F, Fiori G, Matucci-Cerinic M, Bruni C. Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience. Ther Adv Musculoskelet Dis. 2021 May 10;13:1759720X211014019. doi: 10.1177/1759720X211014019. eCollection 2021. PMID: 34025783; PMCID: PMC8120535.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 83 entries